English Deutsch 中文
XinTech
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
XinTech
Menu Deutsch 中文

Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment

Sep. 6, 2013

Hua Medicine announced that it has begun a China Phase I clinical trial of a novel Glucokinase activator treatment for Type II diabetes. The CFDA gave HMS5552, as the Hua drug is known, the designation of type 1.1 novel drug because no drug of the Glucokinase activator class has been approved anywhere in the world. Hua in-licensed China rights to the drug from Roche two years ago.